⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13465078 | 1.00 | — | — | |
| SCHEMBL6628720 | 0.75 | — | — | |
| SCHEMBL167424 | 0.75 | — | — | |
| SCHEMBL20436910 | 0.75 | — | — | |
| SCHEMBL14357989 | 0.75 | MAPK1 (0.32) | — | |
| SCHEMBL4645590 | 0.72 | MAPK1 (0.48) | — | |
| SCHEMBL22408569 | 0.72 | MAPK1 (0.48) | — | |
| SCHEMBL22408568 | 0.72 | MAPK1 (0.48) | — | |
| SCHEMBL13972335 | 0.72 | MAPK1 (0.48) | — | |
| SCHEMBL4988213 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015380-A | Polycyclic IRAK and flt3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2023-11-07 | — | — | CN | disclosed |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| CN-102947289-B | Arylethynyl derivatives | HOFFMANN LA ROCHE | 2014-06-11 | — | — | CN | disclosed |
| CN-102947289-A | Arylethynyl derivatives | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070185336-A1 | Process for preparing n-protected 4-ketoproline derivatives | DEGUSSA AG (DE) | 2007-08-09 | — | — | US | disclosed |